| Autor: |
Johannes Kahrs, Tobias Gedde Dahl, Waleed Ghanima, Geir E. Tjønnfjord |
| Rok vydání: |
2004 |
| Předmět: |
|
| Zdroj: |
European Journal of Haematology. 72:441-443 |
| ISSN: |
0902-4441 |
| DOI: |
10.1111/j.1600-0609.2004.00257.x |
| Popis: |
A 58-yr-old woman was diagnosed with Ph(+) chronic myeloid leukaemia in May 2001. She was initially treated with hydroxyurea and subsequently with interferon-alpha (IFN-alpha). Imatinib mesylate was started in April 2002 after failure of IFN-alpha to induce a cytogenetic response. The patient remained on treatment with imatinib mesylate for 3 months during which she suffered daily fever resulting in discontinuation of the treatment. Response evaluation performed shortly after discontinuing imatinib mesylate revealed a complete cytogenetic remission and a substantial molecular response. Fifteen months later, she was still enjoying a major cytogenetic response. This case illustrates that a short course of imatinib mesylate may result in a sustained haematological and cytogenetic response. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
